Isomorphic Labs Seeks $5bn at $50bn Valuation
The Google DeepMind spinout is in talks to raise the sum, though the financing has not closed.
Updated on Nov. 5, 2026 in Biotech
Live Poll
Do you think AI drug discovery will benefit patients more than it risks harm?
Isomorphic Labs, a drug discovery company spun out of Google DeepMind, is in talks to raise about $5bn at a valuation of about $50bn. The financing has not closed, and the company has no drug in human trials.
Why it matters
The reported valuation reflects heavy investor interest in AI-driven drug design, a field where companies are racing to shorten the time needed to find new molecules. Isomorphic's progress from preclinical work to human trials will determine whether that valuation is justified.
Bloomberg reported talks for a round valuing the company at about $50bn, up from $40bn or more in October and following a $2.1bn round led by Thrive Capital in May. The round has not closed, and the company's first clinical trials are projected to begin by the end of 2026.
The players
Isomorphic Labs
A London-based drug discovery company spun out of Google DeepMind in 2021 that uses AI to design new molecules.
Demis Hassabis
The chief executive of Isomorphic Labs and a leading figure in artificial intelligence research who has led Google DeepMind's work on protein structure prediction.
Thrive Capital
A venture capital firm that led Isomorphic Labs' $2.1bn funding round in May.
Chai Discovery
An AI drug discovery startup backed by OpenAI that raised $400m in July.
The details
Isomorphic Labs' drug design engine, IsoDDE, can search for new molecules on a computer in days, building on the AlphaFold protein structure model. The company's drug work remains in preclinical stages, and its chief executive is Demis Hassabis while Max Jaderberg serves as president.
Timeline
2021: Isomorphic Labs is spun out of Google DeepMind.
October: Bloomberg reports early talks at a valuation of $40bn or more.
May: Isomorphic raises $2.1bn in a round led by Thrive Capital.
July: OpenAI-backed Chai Discovery raises $400m.
November 5, 2026: Bloomberg reports talks for a $5bn round at a $50bn valuation.
Big Picture
Isomorphic Labs builds on the AlphaFold protein structure model that DeepMind released, extending that research toward commercial drug design. The company's pursuit of a $50bn valuation tests whether AlphaFold-derived methods can produce drugs that reach human trials.
If Isomorphic's AI-designed molecules reach human trials as projected, patients could eventually see new drug candidates developed faster than through traditional discovery. Investors and readers tracking the sector should watch whether the proposed round closes and whether the company meets its 2026 trial timeline.
The takeaway
AI drug discovery is attracting very large private investment, but valuations now rest on whether preclinical programs become human trials. Tracking clinical milestones will matter more than funding headlines.
What happens next
Isomorphic Labs expects to begin its first clinical trials by the end of 2026, and the proposed $5bn round has not yet closed.
Further reading
For related coverage of AI-driven drug development, see the Biotech section.
Live Poll
Do you think AI drug discovery will benefit patients more than it risks harm?
